Data from the MAJESTIC three trial shows bispecific antibodies achieving progression-free survival rates comparable to CAR-T therapy. This creates a new clinical dilemma, forcing a choice between an immediate, off-the-shelf option for rapid progression versus a one-time therapy with a longer track record, making treatment an individualized decision.
The IntentiMig trial showed that proactively administering tocilizumab with a bispecific antibody resulted in a zero percent incidence of cytokine release syndrome (CRS). This safety improvement could be pivotal for the broader adoption of bispecifics in community oncology settings, which are less equipped to manage severe side effects.
A convergence of data from pivotal trials (MAJESTIC, CARTITUDE) establishes that BCMA-directed therapies, including CAR-T and bispecifics, provide superior outcomes in early relapse. This marks a paradigm shift, making them the new standard of care after initial therapy failure, even in patients refractory to prior common treatments.